<i>RELN</i> SNP rs802787 protects against Aβ‐driven tau pathology, counteracts <i>APOE</i> ε4 effects, and slows cognitive decline in sporadic late‐onset Alzheimer's disease
Our findings suggest that RELN rs802787 confers resilience against Aβ-driven tau pathology and cognitive deterioration in LOAD. The reduced APOEε4-associated tau burden suggests a potential mechanism by which RELN could modulate tau accumulation. To our knowledge, this is the first RELN variant identified as protective in LOAD. Our results suggest that reelin signaling is an important player in AD pathophysiology, underscoring it as a promising target for AD therapeutics.
Authors
- Tharick Ali Pascoal (ORCID: https://orcid.org/0000-0001-9057-8014)
- Christian Limberger (ORCID: https://orcid.org/0000-0002-5160-3886)
- Giovanna Carello‐Collar (ORCID: https://orcid.org/0000-0003-4644-0151)
- Marco Antônio De Bastiani (ORCID: https://orcid.org/0000-0003-3924-5278)
- Thomas Hugentobler Schlickmann
- D N Souza
- Wyllians Vendramini Borelli
- Guilherme Povala
- João Pedro Ferrari‐Souza
- Eduardo R. Zimmer
- Pedro Rosa‐Neto
Institutions
- Universidade Federal do Rio Grande do Sul (BR)
- University of Pittsburgh (US)
- McGill University (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_106073
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00